Letter by Zhang et al Regarding Article, “Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?”

To the Editor:

We read with great interest the recent article by Fauchier et al,1 in which the authors observed a positive net clinical benefit of oral anticoagulation usage for preventing stroke and other thromboembolic events in atrial fibrillation patients with only 1 nongender-related stroke risk factor (CHA2DS2-VASc 1 in males or 2 in females).

Vitamin K antagonist was the only choice of treatment for preventing stroke in these patients with atrial fibrillation. However, vitamin K antagonist has limitations, such as the risk of hemorrhage, narrow range of effective dosage, food–drug interactions, and need for anticoagulation monitoring. In recent years, new oral anticoagulants have been shown with similar efficacy to vitamin K antagonist, but with improved safety, and without requirement for anticoagulation monitoring. Considering these advantages, new oral anticoagulants were recommended by current guidelines over warfarin in patients with nonvalvular atrial fibrillation.2–4 It is interesting to see whether new oral anticoagulants have a better therapeutic safety profile than warfarin in atrial fibrillation patients with only 1 nongender-related stroke risk factor. Further studies may be needed to answer this question.

Disclosures

None.

Letter by Zhang et al Regarding Article, "Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA 2DS2-VASc Risk Factor Be Anticoagulated?"
Hao Zhang, Yong Gang Hao and Gelin Xu

*Stroke*. 2016;47:e238; originally published online August 11, 2016;
doi: 10.1161/STROKEAHA.116.014301

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/47/10/e238

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/